---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-004091"
form_type: "8-K"
ticker: "KLRS"
cik: "0001754068"
company_name: "Kalaris Therapeutics, Inc."
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T05:21:57.974616+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# AlloVir shareholders approve reverse stock split ratio range 1:15–1:35; board to set exact ratio

## Summary
- 96,216,120 votes for, 12,082,172 against, 303,036 abstain; adjournment not needed.
- Reverse split ratio of any whole number between 1:15 and 1:35, effective before Jan 10, 2026.
- Board will determine exact ratio and timing without further shareholder approval.
- Split is in connection with proposed merger with Kalaris Therapeutics, Inc.

## SEC filing metadata
- accession: 0001193125-25-004091
- form_type: 8-K
- ticker: KLRS
- cik: 0001754068
- company_name: Kalaris Therapeutics, Inc.
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1754068/000119312525004091/0001193125-25-004091-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1754068/000119312525004091/d899696d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-004091
- JSON: https://secwatch.observer/filing/0001193125-25-004091.json
- Plain text: https://secwatch.observer/filing/0001193125-25-004091.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.